Art. -Nr.: HY-17371

Oxaliplatin

Name: Oxaliplatin
Brand: MedChemExpress
SKU: HY-17371
Price: 45.00 USD
Availability: InStock
Rating: 5 (237 reviews)

237 Cited Publications

Kundenbewertung

Based on 237 publication(s) in Google Scholar

Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.65%
CAS. Nr.: 61825-94-3
Formel: C₈H₁₄N₂O₄Pt
Molecular Weight:397.29

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Oxaliplatin Chemical Structure

CAS. Nr.: 61825-94-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
- Induced Disease Models
- Clinical Trial
Chemical Information
Publications (237)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll (7)
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: DNA synthesis^[1]

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen :

In Vitro

Oxaliplatin (24-72 hours; 2-128 μM; HCC, HCCLM3 and Hep3B cells) inhibits cell growth and induces apoptosis^[1].
Oxaliplatin (10 μM; 15-240 mins; CEM cells ) induces primary and secondary DNA lesions, including DNA cross-links (ISC) and DNA-protein cross-links (DPC)^[2].
Oxaliplatin (0.01 to 100 μM; 24 hours) potently inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC₅₀ of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Cell Viability Assay^[1]

View Protocol

Cell Line:

HCC, HCCLM3 and Hep3B cells
Concentration:

24, 48 and 72 hours
Incubation Time:

2, 4, 8, 16, 32, 64 and 128 μM
Result:

Decreased cell viability in a dose- and time-dependent manner.

Cell Cycle Analysis^[1]

View Protocol

Cell Line:

HCCLM3 and Hep3B cells
Concentration:

10 μM
Incubation Time:

24 hours
Result:

Increased the percentage of apoptotic cells (17.70% for HCCLM3 cells; 21.19% for Hep3B cells).

Cell Cycle Analysis^[1]

View Protocol

Cell Line:

HCCLM3 cells
Concentration:

10 μM
Incubation Time:

48 hours
Result:

Down-regulated the expression of Bcl-2 and Bcl-xL, and increased the expression of Bax.

In Vivo

Oxaliplatin (5-10 mg/kg; i.p.; for 32 days; nude mice) inhibits tumor growth^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Nude mice^[1]
Dosage:

5 and 10 mg/kg
Administration:

Intraperitoneal injection; for 32 days
Result:

Reduced tumor volume in HCCLM3 tumor xenografts.

Induced Disease Models

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

1. Induction of acute chemotherapy-induced peripheral neuropathy (CINP)^[10]^[11]^[12]

Background

Oxaliplatin induces acute neuropathic pain through a multifaceted mechanism involving disruption of voltage-gated ion channels, activation of TRP channels, suppression of DNA transcription, mitochondrial dysfunction, and increased generation of reactive oxygen species (ROS)^[10].

Specific Modeling Methods

Rats: SD rats
Administration: Oxaliplatin (3, 5, 6 and 10 mg/kg) • i.p. • once
Rats: SD rats
Administration: Oxaliplatin (2 mg/kg) • i.p. • once
Mice: Male CD-1 mice
Administration: Oxaliplatin (10 mg/kg) • i.p. • once
Mice: Male C57BL/6 mice
Administration: Oxaliplatin (3 and 6 mg/kg) • i.p. • once
Mice: Male BALB/c mice
Administration: Oxaliplatin (5 mg/kg) • i.v. • once

Note

Oxaliplatin working solution is typically prepared in 5% glucose solution.

Modeling Indicators

Molecular changes: Activation of TRPA1/TRPM8 channels, voltage-gated Na⁺ channel dysfunction, and mild ROS elevation
Mechanical allodynia: Decreased paw withdrawal threshold (Von Frey test)
Cold allodynia: Decreased paw withdrawal latency (acetone test)
Motor function: No impairment (rotarod test), confirming pain specificity

2. Induction of chronic chemotherapy-induced peripheral neuropathy (CINP)^[10]^[11]^[12]

Background

Oxaliplatin-induced activation of TRPA1 channels on dorsal root ganglion (DRG) neurons triggers Ca²⁺ influx, leading to the accumulation of ROS, mitochondrial DNA (mtDNA) damage, disruption of the electron transport chain, and opening of the mitochondrial permeability transition pore (mPTP). These alterations subsequently impede ATP synthesis and promote neurotoxicity^[10].

Specific Modeling Methods

Rats: SD rats
Administration: Oxaliplatin (2.4 mg/kg) • i.p. • on days 1-3, 6-10, and 13-15
Rats: SD rats
Administration: Oxaliplatin (2 and 4 mg/kg) • i.p. • on days 1, 2, 3, 4, 5
Rats: SD rats
Administration: Oxaliplatin (6 mg/kg) • i.p. • on days 1,3, 5, 7
Rats: SD rats
Administration: Oxaliplatin (2.4, 3.2, and 4 mg/kg) • i.p. • twice weekly for 4.5 weeks
Rats: Wistar rats
Administration: Oxaliplatin (4 mg/kg) • i.p. • twice weekly for 4 weeks
Rats: Wistar rats
Administration: Oxaliplatin (6 mg/kg) • i.p. • once per day for 6 days
Rats: SD rats
Administration: Oxaliplatin (2 mg/kg) • i.v. • once per day for 5 days
Mice: C57BL/6J mice; BALB/c mice; ICR mice
Administration: Oxaliplatin (0.3 and 3 mg/kg) • i.p. • 5 consecutive days, followed by 2 days of rest, for two cycles
Mice: C57BL/6 mice
Administration: Oxaliplatin (3 mg/kg) • i.p. • 3 times per week for 4 weeks
Mice: CD-1 mice
Administration: Oxaliplatin (2.4 mg/kg) • i.p. • 5 consecutive days each week for 2 weeks
Mice: Swiss mice
Administration: Oxaliplatin (6 mg/kg) • i.p. • every 3 days over 6 days

Note

Oxaliplatin is typically prepared in 5% glucose solution.

Modeling Indicators

Molecular changes: Increased ROS levels, activation of TLR4/NF‑κB pathway (TNF‑α, IL‑1β), decreased ATP, and TRPA1 sensitization
Histological changes: Significant loss of intraepidermal nerve fibers (IENF) in hind paw skin
Mechanical allodynia: Decreased paw withdrawal threshold (Von Frey test)
Cold allodynia: Decreased paw withdrawal latency (acetone test)
Motor function: No impairment (rotarod test), confirming pain specificity
Nerve conduction velocity: Decreased sensory nerve conduction velocity (SNCV); normal motor nerve conduction velocity (MNCV)

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 61825-94-3
Appearance Solid
Molecular Weight 397.29
Formel C₈H₁₄N₂O₄Pt
Color White to off-white
SMILES

O=C(O1)C(O[Pt]21[NH2][C@@H]3CCCC[C@H]3[NH2]2)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (237)

All In Vivo Efficacy StudyCell Proliferation/Viability AssayIF

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Signal Transduct Target Ther

Elaiophylin triggers paraptosis and preferentially kills ovarian cancer drug-resistant cells by inducing MAPK hyperactivation. [Abstract]

2022 Sep 12;7(1):317. PMID: 36097006
Signal Transduct Target Ther

Cyst(e)ine in nutrition formulation promotes colon cancer growth and chemoresistance by activating mTORC1 and scavenging ROS. [Abstract]

2021 May 28;6(1):188. PMID: 34045438
Cancer Cell

Dissecting genetic and immune drivers of heterogeneous responses to neoadjuvant immunochemotherapy in gastric cancer. [Abstract]

2026 Apr 13;44(4):809-830.e11. PMID: 41720086
Cancer Cell

Chemotherapy triggers immune evasion by fostering LEPR+ Kupffer cell differentiation in liver metastases. [Abstract]

2026 Mar 9;44(3):658-675.e12. PMID: 41687606
Cancer Cell

Single-cell resolution spatial analysis of antigen-presenting cancer-associated fibroblast niches. [Abstract]

2025 Sep 25:S1535-6108(25)00393-9. PMID: 41005303
Nat Med

Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. [Abstract]

2024 Mar;30(3):749-761. PMID: 38287168

Oxaliplatin purchased from MedChemExpress. Usage Cited in: Nat Med. 2024 Mar;30(3):749-761. [Abstract]

The relative cell viability of shCtl-, shNDUFB8-, and shCEMIP2-transfected cells was detected by XTT assay after paclitaxel plus gemcitabine treatment (A+G), single-agent 5-Fu (5-FU), and the FOLFIRINOX chemotherapy cocktail [FU+IRI+OXA: 5-FU+Irinotecan (SN-38) +Oxaliplatin (50 nM)] for 48h.
Nat Med

Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity. [Abstract]

2019 Sep;25(9):1428-1441. PMID: 31501614

Oxaliplatin purchased from MedChemExpress. Usage Cited in: Nat Med. 2019 Sep;25(9):1428-1441. [Abstract]

Quantification of CD3+IFN-γ+ T cells in lung lobes taken from urethane-induced primary lung cancer models (n = 5 mice for SD group, n = 6 mice for all the other groups). Three coronal sections containing five pulmonary lobes from each mouse near the maximal diameters are quantified. Each dot represents one view field. A representative result from two independent experiments is shown.
Mol Cancer

Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma. [Abstract]

2024 Jan 10;23(1):12. PMID: 38200517
Nat Mach Intell

2026 Mar 4;8(3):351-371.
Gastroenterology

AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53. [Abstract]

2021 Nov;161(5):1601-1614.e23. PMID: 34303658

Oxaliplatin purchased from MedChemExpress. Usage Cited in: Gastroenterology. 2021 Nov;161(5):1601-1614.e23. [Abstract]

Bar graphs show the GI50 of 5-fluoruracil (48 h), irinotecan (48 h), gemcitabine (48 h), paclitaxel (48 h), and oxaliplatin (48 h) in PDAC cells in combination with bioactive hexapeptides (NTAIYY and PTTIYY) or controls (saline and NTAIYA).
Adv Mater

Efficacy and Safety Assessment of 5-Fluorouracil, Irinotecan and Oxaliplatin-Loaded Implants in Mouse and Pig Models for Pancreatic Cancer Therapy. [Abstract]

2026 Mar 15:e22617. PMID: 41834342
Nat Cancer

Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy. [Abstract]

2022 Sep;3(9):1052-1070. PMID: 35773527
Cell Mol Immunol

Arsenic trioxide elicits prophylactic and therapeutic immune responses against solid tumors by inducing necroptosis and ferroptosis. [Abstract]

2023 Jan;20(1):51-64. PMID: 36447031

Oxaliplatin purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2023 Jan;20(1):51-64. [Abstract]

Comparison of drug (Epirubicin hydrochloride, EPI; Daunorubicin hydrochloride, DNR; Vinorelbine ditartrate, VNR; Oxaliplatin, OXA; Vincristine, VCR; Artemisinin, ART; Colchicine, COL) cytotoxicity to TC1 cells at the indicated doses and time points measured with CCK-8 assays. R.U. (Relative unit) was calculated from the average O.D. values in each condition as the indicator of cell viability (n = 3).
JAMA Oncol

Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. [Abstract]

2022 Jan 1;8(1):e215445. PMID: 34792531
Cell Host Microbe

Bacteroides fragilis promotes chemoresistance in colorectal cancer, and its elimination by phage VA7 restores chemosensitivity. [Abstract]

2025 Jun 11;33(6):941-956.e10. PMID: 40446807
Nat Cell Biol

Trafficking circuit of CD8+ T cells between the intestine and bone marrow governs antitumour immunity. [Abstract]

2024 Aug;26(8):1346-1358. PMID: 39039181
Cancer Res

A RIPK3-PGE2 Circuit Mediates Myeloid-Derived Suppressor Cell-Potentiated Colorectal Carcinogenesis. [Abstract]

2018 Oct 1;78(19):5586-5599. PMID: 30012671
Drug Resist Updat

CEA-induced PI3K/AKT pathway activation through the binding of CEA to KRT1 contributes to oxaliplatin resistance in gastric cancer. [Abstract]

2025 Jan:78:101179. PMID: 39644827

Oxaliplatin purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2025 Jan:78:101179. [Abstract]

Oxaliplatin (100 nM-4 μM; 48 h) inhibits CEA^high (AGS) and CEA^-⁠/lo (xhGC1) gastric cancer cells, with IC50 values of 150 nM and 2.2 μM, respectively.
Nat Commun

2026 May 28.
Nat Commun

Ferroptosis-armed dendritic cell vaccines for glioma immunotherapy. [Abstract]

2026 May 7. PMID: 42098128
Nat Commun

Cleavage of CAD by caspase-3 determines the cancer cell fate during chemotherapy. [Abstract]

2025 May 30;16(1):5006. PMID: 40442064
Nat Commun

THBS1-producing tumor-infiltrating monocyte-like cells contribute to immunosuppression and metastasis in colorectal cancer. [Abstract]

2023 Sep 25;14(1):5534. PMID: 37749092
Cell Discov

Single-cell profiling reveals molecular basis of malignant phenotypes and tumor microenvironments in small bowel adenocarcinomas. [Abstract]

2022 Sep 14;8(1):92. PMID: 36104333
Redox Biol

p53 and fatty acids collaborate to trigger ferroptosis via the FBXO2-FABP5 axis in colorectal cancer. [Abstract]

2026 Mar:90:104043. PMID: 41604941
Redox Biol

Redistribution of defective mitochondria-mediated dihydroorotate dehydrogenase imparts 5-fluorouracil resistance in colorectal cancer. [Abstract]

2024 Jul:73:103207. PMID: 38805974
Gut Microbes

Fusobacterium nucleatum induces chemoresistance in colorectal cancer by inhibiting pyroptosis via the Hippo pathway. [Abstract]

2024 Jan-Dec;16(1):2333790. PMID: 38533566
J Nanobiotechnology

Oxygen vacancy-engineered bimetallic nanozymes for disrupting electron transport chain and synergistic multi-enzyme activity to reverse oxaliplatin resistance in colorectal cancer. [Abstract]

2025 May 16;23(1):352. PMID: 40380190
J Nanobiotechnology

Photoacoustic mediated multifunctional tumor antigen trapping nanoparticles inhibit the recurrence and metastasis of ovarian cancer by enhancing tumor immunogenicity. [Abstract]

2022 Nov 3;20(1):468. PMID: 36329515
J Exp Clin Cancer Res

Pyrotinib targeted EGFR/GRP78 mediated cell apoptosis in high EGFR gene copy number gastric cancer. [Abstract]

2025 Aug 19;44(1):245. PMID: 40830980
J Exp Clin Cancer Res

Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist. [Abstract]

2022 Oct 14;41(1):302. PMID: 36229853
J Exp Clin Cancer Res

Pharmacological targeting PTK6 inhibits the JAK2/STAT3 sustained stemness and reverses chemoresistance of colorectal cancer. [Abstract]

2021 Sep 22;40(1):297. PMID: 34551797
J Exp Clin Cancer Res

miR-19b-3p promotes colon cancer proliferation and oxaliplatin-based chemoresistance by targeting SMAD4: validation by bioinformatics and experimental analyses. [Abstract]

2017 Sep 22;36(1):131. PMID: 28938919
Adv Sci (Weinh)

2026 Jul 13:e76478. PMID: 42439460
Adv Sci (Weinh)

Deep Learning-Powered Scalable Cancer Organ Chip for Cancer Precision Medicine. [Abstract]

2026 Feb 3:e16660. PMID: 41632021
Adv Sci (Weinh)

PRMT5 Inhibitor Synergizes with Chemotherapy to Induce Resembling Mismatch Repair Deficiency and Enhance Anti-TIGIT Therapy in Microsatellite-Stable Colorectal Cancer. [Abstract]

2025 Jul;12(27):e2500271. PMID: 40344511
Adv Sci (Weinh)

Lactylation of HDAC1 Confers Resistance to Ferroptosis in Colorectal Cancer. [Abstract]

2025 Mar;12(12):e2408845. PMID: 39888307
Adv Sci (Weinh)

DNMT3a Downregulation Ttriggered Upregulation of GABAA Receptor in the mPFC Promotes Paclitaxel-Induced Pain and Anxiety in Male Mice. [Abstract]

2025 Feb;12(5):e2407387. PMID: 39679872
Adv Sci (Weinh)

YY2/BUB3 Axis promotes SAC Hyperactivation and Inhibits Colorectal Cancer Progression via Regulating Chromosomal Instability. [Abstract]

2024 Jul;11(26):e2308690. PMID: 38682484
MedComm (2020)

Gallium complex K6 inhibits colorectal cancer by increasing ROS levels to induce DNA damage and enhance phosphatase and tensin homolog activity. [Abstract]

2024 Jul 24;5(8):e665. PMID: 39049965
Adv Sci (Weinh)

Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4-mediated Ferroptosis in Colorectal Cancer. [Abstract]

2023 Sep;10(25):e2301088. PMID: 37428466
Adv Sci (Weinh)

Micro-Engineered Organoid-on-a-Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients. [Abstract]

2023 Sep;10(27):e2302640. PMID: 37485650
Cell Rep Med

Sex-biased intratumoral microbiome influences tumor molecular and immune landscape and disease outcomes. [Abstract]

2026 May 19;7(5):102757. PMID: 42013847
Cell Rep Med

Enhancing gastric cancer immunotherapy: Insights from multi-omics analysis and innovations in photodynamic-chemotherapy nanoplatforms. [Abstract]

2026 Mar 17;7(3):102635. PMID: 41747719
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 15;6(4):102053. PMID: 40187357
Cell Death Differ

Cell death-induced release of the pro-aging protein acyl CoA binding protein (ACBP) into the circulation. [Abstract]

2026 Jun 3. PMID: 42236908
Biomaterials

Immune modulation of the liver metastatic colorectal cancer microenvironment via the oral CAPOX-mediated cGAS-STING pathway. [Abstract]

2024 Oct:310:122625. PMID: 38820768
Chem Eng J

2025 Jun 6.
Chem Eng J

2023 Nov 17, 147466.
J Control Release

Oxygen and oxaliplatin-loaded nanoparticles combined with photo-sonodynamic inducing enhanced immunogenic cell death in syngeneic mouse models of ovarian cancer. [Abstract]

2021 Apr 10:332:448-459. PMID: 33662456
Cell Death Dis

Glutamine metabolic stress induces SLC25A6-dependent mitofission via MIC60-MIC19 complex disassembly in colorectal cancer. [Abstract]

2026 Apr 23;17(1):537. PMID: 42020360
Cell Death Dis

PMEPA1 modulates YAP1 nuclear translocation to disrupt EMT subtypes and promote metastasis in Biliary tract cancer. [Abstract]

2026 Apr 3;17(1):449. PMID: 41932868
Cell Death Dis

The EHMT2-MBLAC2 axis suppresses ribosomal DNA transcription in response to nucleolar DNA damage. [Abstract]

2026 Mar 18;17(1):320. PMID: 41851073
Pharmacol Res

CDC7 stabilized by KRAS signaling reactivation impairs chemosensitivity in KRAS-mutant colorectal cancer. [Abstract]

2025 Dec:222:108027. PMID: 41207349
Cell Death Dis

Chemotherapy-induced macrophage CXCL7 expression drives tumor chemoresistance via the STAT1/PHGDH-serine metabolism axis and SAM paracrine feedback to M2 polarization. [Abstract]

2025 May 14;16(1):379. PMID: 40368902
Cell Death Dis

Mitochondrial, metabolic and bioenergetic adaptations drive plasticity of colorectal cancer cells and shape their chemosensitivity. [Abstract]

2025 Apr 5;16(1):253. PMID: 40185729
Cell Death Dis

Peroxisomal membrane protein PMP70 confers drug resistance in colorectal cancer. [Abstract]

2025 Apr 14;16(1):293. PMID: 40229252
Cell Death Dis

Inhibition of KLF5 promotes ferroptosis via the ZEB1/HMOX1 axis to enhance sensitivity to oxaliplatin in cancer cells. [Abstract]

2025 Jan 18;16(1):28. PMID: 39827156
Cell Death Dis

Hypermethylation of CDKN2A CpG island drives resistance to PRC2 inhibitors in SWI/SNF loss-of-function tumors. [Abstract]

2024 Nov 5;15(11):794. PMID: 39500892
Pharmacol Res

Time-dependent proteomics and drug response in expanding cancer cells. [Abstract]

2024 Jun:204:107208. PMID: 38729587
Cell Death Dis

Upregulation of CRABP2 by TET1-mediated DNA hydroxymethylation attenuates mitochondrial apoptosis and promotes oxaliplatin resistance in gastric cancer. [Abstract]

2022 Oct 4;13(10):848. PMID: 36195596
Cell Death Dis

ECHS1, an interacting protein of LASP1, induces sphingolipid-metabolism imbalance to promote colorectal cancer progression by regulating ceramide glycosylation. [Abstract]

2021 Oct 6;12(10):911. PMID: 34615856
Cell Death Dis

MCT1 relieves osimertinib-induced CRC suppression by promoting autophagy through the LKB1/AMPK signaling. [Abstract]

2019 Aug 13;10(8):615. PMID: 31409796
Cell Death Dis

YAP-dependent ubiquitination and degradation of β-catenin mediates inhibition of Wnt signalling induced by Physalin F in colorectal cancer. [Abstract]

2018 May 22;9(6):591. PMID: 29789528
Cancer Lett

2026 Jul 10:658:218725. PMID: 42431391
Cancer Lett

Tumor-derived CCL5 recruits CCR1+ macrophages to suppress apoptosis and drive proliferation in duodenal adenocarcinoma. [Abstract]

2025 Dec 1:634:218064. PMID: 41015267
Cancer Lett

HOXC8-activated TRIM22/NF-κB pathway promotes stemness in colorectal cancer. [Abstract]

2026 Jan 28:638:218156. PMID: 41265630
Cancer Lett

Traditional medicine Bazi Bushen potentiates immunosurveillance of senescent liver cancer cells via cGAS-STING signaling activation in macrophages. [Abstract]

2025 Sep 1:627:217544. PMID: 39929434
Cancer Lett

The CAIX inhibitor SLC-0111 exerts anti-cancer activity on gastric cancer cell lines and resensitizes resistant cells to 5-Fluorouracil, taxane-derived, and platinum-based drugs. [Abstract]

2023 Sep 1:571:216338. PMID: 37549770
Cancer Lett

De novo pyrimidine synthesis fuels glycolysis and confers chemoresistance in gastric cancer. [Abstract]

2022 Nov 28:549:215837. PMID: 35921972
Cancer Lett

IRE1α-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells. [Abstract]

2020 Apr 28;476:67-74. PMID: 32061752
J Immunother Cancer

Memory B cell subset shapes antitumor immunity and response to PD-1 blockade in mismatch repair-deficient colorectal cancers. [Abstract]

2026 Jan 8;14(1):e012121. PMID: 41506788
J Immunother Cancer

Targeting VCP enhances colorectal cancer therapy through STING stabilization. [Abstract]

2025 Nov 19;13(11):e012652. PMID: 41260904
J Immunother Cancer

Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC. [Abstract]

2022 Aug;10(8):e004006. PMID: 36002188
Int J Biol Sci

Repurposing Oxiconazole against Colorectal Cancer via PRDX2-mediated Autophagy Arrest. [Abstract]

2022 May 21;18(9):3747-3761. PMID: 35813474
Cell Commun Signal

Transcriptional deregulation by FOXM1-JUP signaling confers dual oncogenic drivers for pancreatic tumorigenesis and therapeutic resistance. [Abstract]

2025 Nov 27;23(1):513. PMID: 41310714
Cell Commun Signal

Activation of mechanosensitive ion channel Piezo1 linking metabolic reprogramming and pro-inflammatory responses in hepatocellular carcinoma. [Abstract]

2025 Jun 13;23(1):280. PMID: 40514668
J Exp Med

Resolvins suppress tumor growth and enhance cancer therapy. [Abstract]

2018 Jan 2;215(1):115-140. PMID: 29191914
Phytomedicine

Huangqi Guizhi Wuwu decoction alleviate Oxaliplatin-Induced Peripheral Neuropathy by adjusting the myelin regeneration. [Abstract]

2025 Sep:145:157039. PMID: 40618490
Phytomedicine

Erianin triggers ferroptosis in colorectal cancer cells by facilitating the ubiquitination and degradation of GPX4. [Abstract]

2025 Apr:139:156465. PMID: 39938177
Phytomedicine

Gegen Qinlian Decoction reverses oxaliplatin resistance in colorectal cancer by inhibiting YTHDF1-regulated m6A modification of GLS1. [Abstract]

2024 Oct:133:155906. PMID: 39089089
Phytomedicine

Compound-composed Chinese medicine of Huachansu triggers apoptosis of gastric cancer cells through increase of reactive oxygen species levels and suppression of proteasome activities. [Abstract]

2024 Jan:123:155169. PMID: 37992493
Adv Healthc Mater

Decellularized Extracellular Matrix Scaffolds to Engineer the Dormant Landscape of Microscopic Colorectal Cancer Liver Metastasis. [Abstract]

2025 Oct 13:e01791. PMID: 41083747
Acta Biomater

Biomimetic adhesive hydrogel microcarriers for gas therapy and chemotherapy of gastric cancer. [Abstract]

2026 Jul:218:378-388. PMID: 42285389
Acta Pharmacol Sin

Calcipotriol abrogates cancer-associated fibroblast-derived IL-8-mediated oxaliplatin resistance in gastric cancer cells via blocking PI3K/Akt signaling. [Abstract]

2023 Jan;44(1):178-188. PMID: 35676532
Acta Biomater

Metal-organic framework-mediated multifunctional nanoparticles for combined chemo-photothermal therapy and enhanced immunotherapy against colorectal cancer. [Abstract]

2022 May;144:132-141. PMID: 35307591
Acta Pharmacol Sin

Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]

2021 Jan;42(1):108-114. PMID: 32398685
J Transl Med

Fusobacterium nucleatum enhances oxaliplatin resistance in colon cancer by increasing PVT1 expression. [Abstract]

2025 Oct 16;23(1):1112. PMID: 41102802
Proc Natl Acad Sci U S A

Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain. [Abstract]

2017 Mar 7;114(10):E1825-E1832. PMID: 28223528
Nano Res

2025 Oct.
Dev Cell

2026 Jun 10.
Oncogene

USP10-mediated Ku70/80 stabilization inhibits PANoptosis and promotes chemoresistance in colorectal cancer. [Abstract]

2025 Sep 18. PMID: 40968255
Oncogene

Aberrant FAM135B attenuates the efficacy of chemotherapy in colorectal cancer by modulating SRSF1-mediated alternative splicing. [Abstract]

2024 Nov;43(48):3532-3544. PMID: 39397154
Apoptosis

Nicotine suppresses ferroptosis in colon cancer cells via HMOX1/NF-κB pathway to reduce oxaliplatin sensitivity. [Abstract]

2026 Mar 19;31(3):102. PMID: 41851365
Cell Chem Biol

Pharmacological Targeting of Vacuolar H+-ATPase via Subunit V1G Combats Multidrug-Resistant Cancer. [Abstract]

2020 Nov 19;27(11):1359-1370.e8. PMID: 32649904
Int J Nanomedicine

SiRNF8 Delivered by DNA Framework Nucleic Acid Effectively Sensitizes Chemotherapy in Colon Cancer. [Abstract]

2024 Jan 6:19:171-188. PMID: 38204601
Int J Nanomedicine

The Destruction Of Laser-Induced Phase-Transition Nanoparticles Triggered By Low-Intensity Ultrasound: An Innovative Modality To Enhance The Immunological Treatment Of Ovarian Cancer Cells. [Abstract]

2019 Dec 2:14:9377-9393. PMID: 31819438
Int J Mol Med

Exportin 1 inhibitor KPT‑330 reverses oxaliplatin resistance via p53 nuclear retention in colorectal cancer. [Abstract]

2026 Jan;57(1):4. PMID: 41133455
Mol Ther Oncol

A KRASG12V-targeted bispecific T cell engager promotes immunity against colorectal solid tumor. [Abstract]

2025 Nov 22;33(4):201098. PMID: 41438133
Mol Med

Knockdown of SLC7A5 inhibits malignant progression and attenuates oxaliplatin resistance in gastric cancer by suppressing glycolysis. [Abstract]

2025 Mar 25;31(1):115. PMID: 40133832
View

2023 Nov 15.
ACS Appl Mater Interfaces

Primary Human Gastric Cancer Cells Integrated Hydrogel Microcapsules for Personalized Drug Screening. [Abstract]

2026 Feb 11;18(5):7900-7909. PMID: 41615381
Cell Rep

Pharmacological boosting of cGAS activation sensitizes chemotherapy by enhancing antitumor immunity. [Abstract]

2023 Mar 20;42(3):112275. PMID: 36943864
Cell Rep

Redox-sensitive cyclophilin A elicits chemoresistance through realigning cellular oxidative status in colorectal cancer. [Abstract]

2021 Nov 30;37(9):110069. PMID: 34852234
Int J Oncol

Establishment and characteristics of GWH04, a new primary human glioblastoma cell line. [Abstract]

2022 Nov;61(5):139. PMID: 36169178
J Med Chem

Selective Penicillamine Substitution Enables Development of a Potent Analgesic Peptide that Acts through a Non-Opioid-Based Mechanism. [Abstract]

2021 Jul 8;64(13):9271-9278. PMID: 34142837
J Med Chem

Development of Conformationally Constrained α-RgIA Analogues as Stable Peptide Antagonists of Human α9α10 Nicotinic Acetylcholine Receptors. [Abstract]

2020 Aug 13;63(15):8380-8387. PMID: 32597184
Cancer Cell Int

Establishment and characteristic analysis of a novel patient derived cell line of intrahepatic cholangiocarcinoma. [Abstract]

2025 Oct 15;25(1):357. PMID: 41094661
Cancer Cell Int

Identification of E3 ubiquitin ligase-based molecular subtypes and prognostic signature regarding prognosis and immune landscape in bladder cancer. [Abstract]

2025 Feb 27;25(1):70. PMID: 40016750
Mol Cancer Ther

Functional genomics and proteomics identify Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in diverse T-cell lymphoma models. [Abstract]

2026 Jun 13. PMID: 42295240
Mol Cancer Ther

Mosperafenib, a novel paradox breaker BRAF inhibitor with potent preclinical activity in BRAF mutated colorectal cancer. [Abstract]

2025 Dec 4. PMID: 41340484
Mol Cancer Ther

PIN1 Inhibition Sensitizes Chemotherapy in Gastric Cancer Cells by Targeting Stem Cell-like Traits and Multiple Biomarkers. [Abstract]

2020 Mar;19(3):906-919. PMID: 31879364
J Ethnopharmacol

Overcoming multi drug resistance mediated by ABC transporters by a novel acetogenin- annonacin from Annona muricata L. [Abstract]

2024 Mar 25:322:117598. PMID: 38113989
Biomater Adv

Mesenchymal stem cell-derived small extracellular vesicles loaded with miRNA-4488 alleviate chemotherapy-induced premature ovarian insufficiency via mitigation of apoptosis and oxidative stress. [Abstract]

2026 Apr:181:214656. PMID: 41406654
Biomater Adv

Thermosensitive nanogel-based oxaliplatin delivery system for synergistic intratumoral radiofrequency chemotherapy. [Abstract]

2026 May:182:214726. PMID: 41581319
Eur J Med Chem

Optimization of WZ4003 as NUAK inhibitors against human colorectal cancer. [Abstract]

2021 Jan 15:210:113080. PMID: 33310286
Ecotoxicol Environ Saf

PPARγ-responsive luciferase reporter system for high-throughput screening of chemical toxins with potential pulmonary fibrosis effects. [Abstract]

2025 Nov 15:307:119433. PMID: 41273832
Biochem Pharmacol

Discovery of a potent BRD4 PROTAC and evaluation of its bioactivity in breast cancer cell lines. [Abstract]

2025 Nov:241:117159. PMID: 40659131
Cell Biosci

Cholesterol confers resistance to Apatinib-mediated ferroptosis in gastric cancer. [Abstract]

2025 Jul 4;15(1):95. PMID: 40615893
Cell Biosci

MIIP downregulation drives colorectal cancer progression through inducing peri-cancerous adipose tissue browning. [Abstract]

2024 Jan 20;14(1):12. PMID: 38245780
Precis Clin Med

Agrimol B inhibits pancreatic ductal adenocarcinoma by induction of lethal mitophagy through decreasing mitochondrial transcription termination factor 3. [Abstract]

2026 Mar 14;9(2):pbag009. PMID: 41978696
Biosensors (Basel)

FAP-Anchored Retinoic Acid Nanoparticles for Stromal Reprogramming and Enhanced Intratumoral Oxaliplatin Delivery in Fibrotic Colorectal Tumours. [Abstract]

2026 Mar 25;16(4):189. PMID: 42041410
J Cell Biol

Real-time imaging of RNA polymerase I activity in living human cells. [Abstract]

2023 Jan 2;222(1):e202202110. PMID: 36282216
Cells

Machine Learning-Driven Multi-Omics Analysis Identifies CHP2 as a Key PANoptosis-Related Dual-Function Biomarker in Colorectal Cancer. [Abstract]

2026 Feb 28;15(5):430. PMID: 41827864
Oncogenesis

NFATc1-mediated activation of the pentose phosphate pathway and cell cycle dysregulation collectively drive tumor progression. [Abstract]

2025 Nov 7;14(1):39. PMID: 41203626
Cells

RgIA4 Prevention of Acute Oxaliplatin-Induced Cold Allodynia Requires α9-Containing Nicotinic Acetylcholine Receptors and CD3+ T-Cells. [Abstract]

2022 Nov 11;11(22):3561. PMID: 36428990
Commun Biol

Structural basis of Fumosorinone-mediated allosteric inhibition of PTP1B for cancer immunotherapy. [Abstract]

2026 May 28;9(1):729. PMID: 42209755
Commun Biol

Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays. [Abstract]

2024 Dec 3;7(1):1612. PMID: 39627437
Eur J Pharmacol

Compound Z526 alleviates chemotherapy-induced cachectic muscle loss by ameliorating oxidative stress-driven protein metabolic imbalance and apoptosis. [Abstract]

2024 Jul 5:974:176538. PMID: 38552940
Mar Drugs

Ascomylactam C Induces an Immunogenic Cell Death Signature via Mitochondria-Associated ER Stress in Lung Cancer and Melanoma. [Abstract]

2023 Nov 21;21(12):600. PMID: 38132921
Clin Epigenetics

Identification of hepatocellular carcinoma subtypes based on PcG-related genes and biological relevance with cancer cells. [Abstract]

2022 Dec 24;14(1):184. PMID: 36566204
Int J Mol Sci

LRRC8A Inhibition Overcomes Chemoresistance by Downregulating MRP3 and CYP3A4 in the 3D Spheroid Model of Human Breast Cancer Cells. [Abstract]

2026 Mar 13;27(6):2646. PMID: 41898509
Int J Mol Sci

Gene Expression Profiling of Pancreatic Ductal Adenocarcinoma Cells in Hypercapnia Identifies SIAH3 as a Novel Prognostic Biomarker. [Abstract]

2025 Mar 21;26(7):2848. PMID: 40243415
Int Immunopharmacol

A novel Senescence-Based prognostic model unveils tumor interactions and drug resistance in colorectal cancer. [Abstract]

2024 Jun 15:134:112197. PMID: 38733826
Int J Mol Sci

Proteomic Profiling of Chemotherapy Responses in FOLFOX-Resistant Colorectal Cancer Cells. [Abstract]

2023 Jun 8;24(12):9899. PMID: 37373047
Neurochem Int

Repeated administration of esketamine ameliorates mechanical allodynia in mice with chemotherapy-induced peripheral neuropathy: A role of gut microbiota and metabolites. [Abstract]

2025 May:185:105961. PMID: 40054499
Biol Direct

Integrative genomics unveils basement membrane-related diagnostic markers and therapeutic targets in esophageal squamous cell carcinoma. [Abstract]

2024 Sep 11;19(1):79. PMID: 39256753
Food Hydrocoll Health

2025 Jun.
ACS Omega

A LRELHLNNN-Gal‑3 Modified Adipose Decellularized Scaffold To Construct Colorectal Cancer Model for Anticancer Drug Screening and Immunotherapy. [Abstract]

2025 Oct 30;10(44):52931-52943. PMID: 41244442
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Sci Rep

Targeting colorectal cancer with pyrazolo[4,3-e][1,2,4]triazine and pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine sulfonamides: comprehensive in vitro evaluation. [Abstract]

2026 May 31. PMID: 42225755
Sci Rep

Chemotherapy-derived DAMPs drive reprogramming of tumor-associated macrophages toward a pro-inflammatory phenotype in hepatocellular carcinoma. [Abstract]

2026 Apr 3;16(1):17440. PMID: 41933190
Transl Oncol

Triptonide stabilizes BIM to enhance oxaliplatin-induced ferroptosis and apoptosis in colorectal cancer. [Abstract]

2025 Oct:60:102491. PMID: 40773827
Sci Rep

miR-340 reverses chemotherapy resistance in colon cancer via the PDCD4/WNT/β-catenin signalling pathway. [Abstract]

2025 Sep 29;15(1):33421. PMID: 41022995
Sci Rep

Biological and genetic characterization of a newly established human primary multidrug-resistant distal cholangiocarcinoma cell line, CBC3T-6. [Abstract]

2024 Nov 29;14(1):29661. PMID: 39613883
Sci Rep

Nrf2 inhibition increases sensitivity to chemotherapy of colorectal cancer by promoting ferroptosis and pyroptosis. [Abstract]

2023 Sep 1;13(1):14359. PMID: 37658132
Cancer Sci

D-1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity. [Abstract]

2023 Jul;114(7):2951-2960. PMID: 37158138
Int J Cancer

Long noncoding RNA CCAL transferred from fibroblasts by exosomes promotes chemoresistance of colorectal cancer cells. [Abstract]

2020 Mar 15;146(6):1700-1716. PMID: 31381140
Sci Rep

Shikonin induces mitochondria-mediated apoptosis and enhances chemotherapeutic sensitivity of gastric cancer through reactive oxygen species. [Abstract]

2016 Dec 1:6:38267. PMID: 27905569
Spectrochim Acta A Mol Biomol Spectrosc

2026 Dec 15;363(Pt 2):128470. PMID: 42492432
Neoplasia

MYH knockdown in pancreatic cancer cells creates an exploitable DNA repair vulnerability. [Abstract]

2025 Mar:61:101138. PMID: 39938155
Cancers (Basel)

In Vitro and In Silico Investigation of BCI Anticancer Properties and Its Potential for Chemotherapy-Combined Treatments. [Abstract]

2023 Sep 6;15(18):4442. PMID: 37760412
Cancers (Basel)

HuR Plays a Role in Double-Strand Break Repair in Pancreatic Cancer Cells and Regulates Functional BRCA1-Associated-Ring-Domain-1(BARD1) Isoforms. [Abstract]

2022 Apr 6;14(7):1848. PMID: 35406624
Oncol Rep

Cryopreserved biopsy tissues of rectal cancer liver metastasis for assessment of anticancer drug response in vitro and in vivo. [Abstract]

2020 Feb;43(2):405-414. PMID: 31894341
Mol Oncol

Patient therapy outcome modeling in cancer organoids is improved by cancer-associated fibroblasts and organoid assembly convolution. [Abstract]

2026 Jun 5. PMID: 42246237
iScience

Screening and molecular mechanism research on bile microRNAs associated with chemotherapy efficacy in perihilar cholangiocarcinoma. [Abstract]

2024 Dec 4;27(12):111437. PMID: 39717085
Mol Oncol

Optimized low-dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment. [Abstract]

2020 Nov;14(11):2894-2919. PMID: 33021054

Oxaliplatin purchased from MedChemExpress. Usage Cited in: Mol Oncol. 2020 Nov;14(11):2894-2919. [Abstract]

FOLFOX was administered as 6 mg/kg Oxaliplatin two hours before administration of 90 mg/kg Leucovorin and 50 mg/kg 5-Fluorouracil at day 1 and a repeat of 5‐Fluorouracil dosing on day 2. Weight loss of ODC-, CTRL-, and FOLFOX-treated mice over time of mice with DLD1 tumors.
Front Cell Neurosci

RgIA4 Potently Blocks Mouse α9α10 nAChRs and Provides Long Lasting Protection against Oxaliplatin-Induced Cold Allodynia. [Abstract]

2017 Jul 21:11:219. PMID: 28785206
Biochim Biophys Acta Mol Cell Res

Reduced store operated calcium entry contributes to autophagy mediated escape of prostate cancer to oxaliplatin treatment. [Abstract]

2025 Jun;1872(5):119953. PMID: 40189057
Biochim Biophys Acta Mol Cell Res

DHRS2-induced SPHK1 downregulation contributes to the cell growth inhibition by Trichothecin in colorectal carcinoma. [Abstract]

2024 Dec;1871(8):119846. PMID: 39284549
FEBS J

The sulfonamide anticancer agent indisulam enhances the chemosensitivity of gastric cancer cells by targeting FKBP8. [Abstract]

2026 Mar 20. PMID: 41860182
FEBS J

Oxaliplatin accelerates immunogenic cell death by activating the cGAS/STING/TBK1/IRF5 pathway in gastric cancer. [Abstract]

2025 Apr 22. PMID: 40260556
Cancer Res Treat

Establishment of Patient-Derived Organoids Using Ascitic or Pleural Fluid from Cancer Patients. [Abstract]

2023 Oct;55(4):1077-1086. PMID: 37309112
BMC Cancer

Individualized drug screening in cholangiocarcinoma using organoid models and patient-derived tumor xenograft. [Abstract]

2025 Dec 31. PMID: 41469951
Pharm Res

Active Targeting of Colorectal Cancer Using Chemotherapy-Loaded Nanoparticles Functionalized with a Folate Receptor-α (FRα) Ligand, Pemetrexed. [Abstract]

2025 Nov 18. PMID: 41254319
BMC Cancer

A quinoline-2-thione derivative as a novel chemotherapy drug candidate displays anti-tumor activity in vitro and in vivo. [Abstract]

2024 Oct 13;24(1):1272. PMID: 39397012
Clin Immunol

Integrated analysis of tumour-derived exosome-related immune genes to predict progression and immune status of hepatocellular carcinoma. [Abstract]

2023 Nov:256:109774. PMID: 37774907
ACS Pharmacol Transl Sci

T‑Cell Immunoreceptor with Ig and Immunoreceptor Tyrosine-Based Inhibitory Motif Domains/Cluster of Differentiation 40 Cellular Nanovesicles Carrying Oxaliplatin Exhibited Superior Pancreatic Cancer Cells Therapy. [Abstract]

2026 Mar 28;9(4):1010-1020. PMID: 41988365
Naunyn Schmiedebergs Arch Pharmacol

Enhancing sensitivity to oxaliplatin in tongue squamous cell carcinoma: mechanistic insights and therapeutic potential of DHA combination therapy. [Abstract]

2025 Apr;398(4):4393-4407. PMID: 39476243
ACS Pharmacol Transl Sci

α9-Containing Nicotinic Acetylcholine Receptors Are Required for RgIA-5474 Attenuation of Chemotherapy-Induced Neuropathic Pain. [Abstract]

2024 Nov 12;7(12):3935-3944. PMID: 39698293
Pathol Res Pract

SIRT3 promotes oxaliplatin sensitivity in hepatocellular carcinoma by promoting ferroptosis through endoplasmic reticulum stress response. [Abstract]

2026 May:281:156400. PMID: 41775211
J Biomed Res

Hypoxia-induced acidic microenvironment alters cellular pharmacokinetics of gastric cancer in a Mongolian population. [Abstract]

2026 Apr 25:1-18. PMID: 41953981
Pathol Res Pract

ETV4 promotes the growth, metastasis, glycolysis, and oxaliplatin resistance of colorectal cancer by transcription activation-mediated SLC38A5 upregulation. [Abstract]

2025 Jul:271:156033. PMID: 40435908
Stem Cells Int

lncRNA TUG1 Facilitates Colorectal Cancer Stem Cell Characteristics and Chemoresistance by Enhancing GATA6 Protein Stability. [Abstract]

2021 Nov 23:2021:1075481. PMID: 34858502
J Gastroenterol Hepatol

IKZF3 Promotes Gastric cancer Progression and Oxaliplatin Resistance via PI3K/AKT/mTOR Activation. [Abstract]

2026 Mar 12. PMID: 41820205
Mol Carcinog

Potential Value of AURKA and CDK6 Amplification for the Response of Patients With Gastric Cancer to Neoadjuvant Chemotherapy. [Abstract]

2025 Apr 13. PMID: 40222043
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
Mol Carcinog

Down-regulation of aquaporin 5-mediated epithelial-mesenchymal transition and anti-metastatic effect by natural product Cairicoside E in colorectal cancer. [Abstract]

2017 Dec;56(12):2692-2705. PMID: 28833571
Digestion

KIF4A Facilitates Oxaliplatin Resistance and Stemness in Colon Cancer by Boosting Glucose Metabolism. [Abstract]

2025;106(5):416-428. PMID: 40147432
Front Oncol

Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine. [Abstract]

2021 Jul 13:11:704042. PMID: 34327143
J Cancer Res Clin Oncol

Cystatin SA attenuates gastric cancer cells growth and increases sensitivity to oxaliplatin via PI3K/AKT signaling pathway. [Abstract]

2024 May 8;150(5):244. PMID: 38717526
Dalton Trans

Oxaliplatin and [Pt(R,R-DACH)(panobinostat-2H)] show nanomolar cytotoxicity towards diffuse intrinsic pontine glioma (DIPG). [Abstract]

2020 May 7;49(17):5703-5710. PMID: 32297619
Mol Biol Rep

FADS2 inhibits colorectal cancer cell proliferation by regulating ferroptosis through SLC7A11/GPX4. [Abstract]

2025 Apr 15;52(1):394. PMID: 40232565
J Inorg Biochem

Bridging pyrimidine hemicurcumin and Cisplatin: Synthesis, coordination chemistry, and in vitro activity assessment of a novel Pt(II) complex. [Abstract]

2024 Nov:260:112702. PMID: 39163714
In Vitro Model

Colorectal carcinoma organoid and cancer-associated fibroblasts co-culture system for drug evaluation. [Abstract]

2025 Mar 5;4(1):31-44. PMID: 40160212
Int J Immunopathol Pharmacol

2026 Jan-Dec:40:3946320261474427. PMID: 42536653
PLoS One

Reducing OGT and O-GlcNAcylation enhance the anticancer effects of oxaliplatin in SW620 metastatic colorectal cancer cells. [Abstract]

2026 Feb 10;21(2):e0341971. PMID: 41666153
Int J Immunopathol Pharmacol

Chemotherapy elevates cell surface PD-L1 and MHC-I expression in apoptotic gastric cancer cells. [Abstract]

2025 Jan-Dec:39:3946320251338662. PMID: 40380807
Biomol Biomed

Periplocin improves the sensitivity of oxaliplatin-resistant hepatocellular carcinoma cells by inhibiting M2 macrophage polarization. [Abstract]

2025 Mar 7;25(4):857-868. PMID: 39207178
Hum Cell

Exosomal circ_0091741 promotes gastric cancer cell autophagy and chemoresistance via the miR-330-3p/TRIM14/Dvl2/Wnt/β-catenin axis. [Abstract]

2023 Jan;36(1):258-275. PMID: 36323918
World J Gastrointest Oncol

Interleukin-22 promotes cancer stemness and chemotherapy resistance in colorectal cancer via epidermal growth factor receptor/extracellular signal-regulated kinase pathway. [Abstract]

2025 Aug 15;17(8):108535. PMID: 40837778
Photodiagnosis Photodyn Ther

The role of autophagy in the treatment of colon cancer by chlorin e6 photodynamic therapy combined with oxaliplatin. [Abstract]

2022 Dec:40:103082. PMID: 36028170
Cancer Rep

Comparison of Gastric Cancer Models Using Different Dimensions In Vitro. [Abstract]

2025 Dec;8(12):e70401. PMID: 41308696
Biochem Biophys Res Commun

Non-cytotoxic nanomolar concentration of arctigenin protects neuronal cells from chemotherapy-induced ferroptosis by regulating SLC7A11-cystine-cysteine axis. [Abstract]

2024 May 28:710:149895. PMID: 38593620
Biochem Biophys Res Commun

Dioscin reduced chemoresistance for colon cancer and analysis of sensitizing targets. [Abstract]

2023 Jan 1:638:94-102. PMID: 36442237
Biochem Biophys Res Commun

The tyrosine phosphatase SHP2 promotes proliferation and oxaliplatin resistance of colon cancer cells through AKT and ERK. [Abstract]

2021 Jul 23:563:1-7. PMID: 34052504
Biocell

2026 Jan 23.
Biol Pharm Bull

Ginsenoside Rg3 Combined with Oxaliplatin Inhibits the Proliferation and Promotes Apoptosis of Hepatocellular Carcinoma Cells via Downregulating PCNA and Cyclin D1. [Abstract]

2019 Jun 1;42(6):900-905. PMID: 30930425
Gastroenterol Res Pract

lncRNA GAU1 Induces GALNT8 Overexpression and Potentiates Colorectal Cancer Progression. [Abstract]

2021 Jun 17:2021:5960821. PMID: 34239555
Int J Clin Exp Pathol

2017;10(3):3033-3042.
bioRxiv

2026 Jul 8.
medRxiv

2026 Apr 18.
bioRxiv

2026 Apr 7.
Res Sq

2026 Mar 5.
Res Sq

2026 Jan 15.
Patent

US20250320299A1.
Biomed Pharmacother

Synergistic enhancement of anticancer effects by periodontal ligament stem cell exosomes and oxaliplatin via apoptosis induction and protein modulation. [Abstract]

2025 Oct:191:118481. PMID: 40834748
bioRxiv

Integrating functional genomics and proteomics identifies Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in T-cell lymphoma. [Abstract]

2025 Oct 9:2025.10.08.681217. PMID: 41279001
bioRxiv

2025 Sep 17.
bioRxiv

2025 Aug 19.
SSRN

2025 Jul 7.
Res Sq

2025 Apr 06.
bioRxiv

A whole genomic CRISPR-Cas9 screen identifies the amino acid transporter SLC43A1 (LAT3) as a major determinant of oxaliplatin sensitivity in colorectal cancer cells. [Abstract]

2025 Apr 24:2025.04.21.649594. PMID: 40568133
bioRxiv

2025 January 16.
bioRxiv

Paired primary-metastasis patient-derived organoids and mouse models identify phenotypic evolution and druggable dependencies of peritoneal metastasis from appendiceal cancer. [Abstract]

2025 Feb 22:2025.02.17.638725. PMID: 40027618
Patent

US20240342225A1
Res Sq

2024 Aug 11.
Biomed Pharmacother

Expediting the development of robust 5-FU-resistant colorectal cancer models using innovative combined in vivo and in vitro strategies. [Abstract]

2024 Nov:180:117576. PMID: 39442235
Res Sq

2024 Jul 12.
Biomed Pharmacother

Rupatadine inhibits colorectal cancer cell proliferation through the PIP5K1A/Akt/CDK2 pathway. [Abstract]

2024 Jul:176:116826. PMID: 38838507
Biomed Pharmacother

Nanocarrier mediated entinostat and oxaliplatin combination therapy displayed enhanced efficacy against pancreatic cancer. [Abstract]

2024 Jun:175:116743. PMID: 38759290
bioRxiv

2023 Oct 10.
Biomed Pharmacother

Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing. [Abstract]

2023 Jul:163:114751. PMID: 37105073
SSRN

2023 Jun 6.
Heliyon

LRRC8A promotes the initial development of oxaliplatin resistance in colon cancer cells. [Abstract]

2023 Jun 1;9(6):e16872. PMID: 37313175
bioRxiv

2023 Feb 28.
Ann Transl Med

E2F1 inhibits cellular senescence and promotes oxaliplatin resistance in colorectal cancer. [Abstract]

2023 Feb 28;11(4):185. PMID: 36923082
Oxid Med Cell Longev

Vitamin D Promotes Ferroptosis in Colorectal Cancer Stem Cells via SLC7A11 Downregulation. [Abstract]

2023 Feb 16:2023:4772134. PMID: 36846715
bioRxiv

2023 Jan 28.
Heliyon

The potential effects and mechanisms of Gegen Qinlian Decoction in oxaliplatin-resistant colorectal cancer based on network pharmacology. [Abstract]

2022 Oct 30;8(11):e11305. PMID: 36353164
Research Square Print

2022 May.
Bioengineered

Memantine ameliorates oxaliplatin-induced neurotoxicity via mitochondrial protection. [Abstract]

2022 Mar;13(3):6688-6697. PMID: 35235756
Research Square Preprint

2021 Oct.
Patent

US10947274.
Université de Genève

2020 Sep.
Biomed Pharmacother

Mitochondrial DNA content reduction induces aerobic glycolysis and reversible resistance to drug-induced apoptosis in SW480 colorectal cancer cells. [Abstract]

2018 Jul:103:729-737. PMID: 29684851
Tumour Biol

Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells. [Abstract]

2016 Jul;37(7):8811-24. PMID: 26747179

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : 2 mg/mL (5.03 mM; ultrasonic and warming and heat to 60°C; DMSO can inactivate Oxaliplatin's activity)

DMF : 1.67 mg/mL (4.20 mM; Need ultrasonic; DMSO can inactivate Oxaliplatin's activity)

Ethanol : < 1 mg/mL (insoluble; DMSO can inactivate Oxaliplatin's activity)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5171 mL

12.5853 mL

25.1705 mL

5 mM

0.5034 mL

2.5171 mL

5.0341 mL

10 mM

---

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 5% w/v Glucose Solution

Solubility: 3.33 mg/mL (8.38 mM); Clear solution; Need ultrasonic

Protokoll

All Cell Biology Signal Pathway Related

EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (305 KB)
SDS (560 KB)
- English - EN (560 KB)
- Français - FR (560 KB)
- Deutsch - DE (560 KB)
- Norwegian - NO (560 KB)
- Español - ES (560 KB)
- Swedish - SV (560 KB)
- Italian - IT (560 KB)
- Korean - KR (560 KB)
- Portuguese - PT (560 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Raymond E, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998 Oct;9(10):1053-71. [Content Brief]

[2]. Mohammed MQ, et al. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with NSC 119875 and NSC 241240. Anticancer Drugs. 2000 Nov;11(10):859-63. [Content Brief]

[3]. Pendyala L, et al. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 1993 Dec 15;53(24):5970-6. [Content Brief]

[4]. Wang Z, et al. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth. Expert Opin Investig Drugs. 2009 Nov;18(11):1595-604 [Content Brief]

[5]. Mathé G, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum. Biomed Pharmacother. 1989;43(4):237-50. [Content Brief]

[6]. Schellingerhout D, et al. Impairment of retrograde neuronal transport in oxaliplatin-induced neuropathy demonstrated by molecular imaging. PLoS One. 2012;7(9):e45776. doi: 10.1371/journal.pone.0045776. Epub 2012 Sep 20. [Content Brief]

[7]. Park GY, et al. Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile. Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):11987-92. [Content Brief]

[8]. Yi Yao, et al. Comparative proteomic analysis of colon cancer cells in response to oxaliplatin treatment. Biochim Biophys Acta. 2009 Oct;1794(10):1433-40. [Content Brief]

[9]. Garrett MJ, et, al. Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer. Hosp Pharm. 2017 May;52(5):341-347. [Content Brief]

[10]. Jiang Y, et al. Oxaliplatin-induced neuropathic pain in cancer: animal models and related research progress. Front Pharmacol. 2025 May 30;16:1609791. [Content Brief]

[11]. Xiao WH, et al. Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience. 2012 Feb 17;203:194-206. [Content Brief]

[12]. Dehghani S, et al. Neuroinflammatory Mechanisms and Therapeutic Targets in Oxaliplatin-Induced Peripheral Neuropathy: a Comprehensive Review. Neurotox Res. 2025 Dec 13;43(6):52. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMF / H₂O	1 mM	2.5171 mL	12.5853 mL	25.1705 mL	62.9263 mL
H₂O	5 mM	0.5034 mL	2.5171 mL	5.0341 mL	12.5853 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Bioz

Keywords

Oxaliplatin

237 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Oxaliplatin

Publications Citing Use of MedChemExpress (MCE) Oxaliplatin

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen